FDA 483 - Lonza Bend Inc. - May 24, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lonza Bend Inc., a contract drug manufacturer in Bend, OR, revealed significant deficiencies across its quality system. Observations included inadequate controls over computerized systems and data integrity, issues with equipment design and qualification, and a critical failure in component identity testing for drug products, specifically regarding toxic glycol derivatives in pediatric formulations. These findings indicate a high severity of non-compliance impacting product quality and patient safety.
ID · ff6ae813-1b31-4354-be67-294b2f60902c